Hypercholesterolemia Belgium 2025: NF-kB oxLDL, PCSK9, Nrf2 & Ginger

SCIENTIFIC SUMMARY

Hypercholesterolemia is the number 1 cardiovascular risk factor in Belgium (45% of adults have LDL > 3 mmol/L). But ginger cholesterol itself doesn't cause atherosclerosis -- it's oxidized LDL (oxLDL). Mechanism: LDL -> oxidation (ROS) -> oxLDL -> endothelial LOX-1 -> NF-kB -> ICAM-1/MCP-1/IL-6 -> macrophages -> foam cells -> plaque. PCSK9 (proprotein convertase subtilisin/kexin type 9) is the target of new antibodies (evolocumab, alirocumab) and is negatively regulated by NF-kB/Nrf2. 6-Gingerol: reduction of LDL oxidation (NADPH-oxidase inhibition -38%), PCSK9 expression reduction (-28% in vitro), Nrf2/HO-1 activation (endothelial protection), HDL-C stabilization. GIMBER = lipogenic fructose: 35g sugar/100ml -> fructose -> hepatic de novo lipogenesis -> VLDL -> small dense LDL (sdLDL) -> accelerated oxidation -> atherosclerosis. INTI: 1.19g sugar/100ml.

Atherosclerosis & NF-kB: the oxLDL-foam cell cycle

Atherosclerotic plaque is not merely fat accumulation. It is an active inflammatory lesion where endothelial NF-kB acts as the orchestra conductor. Oxidized LDL (oxLDL) binds to the LOX-1 receptor (Lectin-like Oxidized LDL Receptor-1) on the surface of endothelial cells, activating NF-kB. This induces the expression of ICAM-1 (leukocyte adhesion), MCP-1 (monocyte chemoattractant), and IL-6 (systemic inflammation). Attracted monocytes differentiate into macrophages that massively absorb oxLDL and become "foam cells" -- the core of atherosclerotic plaque.

Atherogenic Step NF-kB Mediator Gingerol
LDL Oxidation -> oxLDL NADPH-oxidase -> ROS NADPH-ox -38%, GPx +25%
Leukocyte Adhesion ICAM-1, VCAM-1, E-selectin ICAM-1 -47%, VCAM-1 -39%
Foam Cell Formation oxLDL -> LOX-1 -> NF-kB LOX-1 -35% (6-gingerol)
PCSK9 Overexpression NF-kB -> PCSK9 -> LDL-R downregulation PCSK9 -28% in vitro

Fructose and dyslipidemia: the GIMBER-cardiovascular link

GIMBER = 35g sugar/100ml of which fructose (2nd ingredient).
Fructose is exclusively metabolized in the liver (unlike glucose which goes to all tissues):
- Hepatic de novo lipogenesis -> increased VLDL-C -> small dense LDL (sdLDL) -> oxidation +300% vs large LDL
- Uric acid (by-product) -> xanthine oxidase -> ROS -> extra LDL oxidation
- Hepatic insulin resistance -> increased apo B100 -> more LDL particles
INTI: 1.19g sugar/100ml. No fructose lipogenesis. No atherogenic sdLDL.

Gingerol and statins: documented complementarity

Statins (atorvastatin, rosuvastatin, simvastatin) inhibit HMG-CoA reductase -> less cholesterol synthesis -> LDL-R upregulated. Gingerol works complementarily:

  • Nrf2/HO-1: endothelial protection independent of statins
  • PCSK9 downregulation: synergistic with statins (less LDL-R degradation)
  • Anti-oxLDL: reduces the initial atherogenic step (statins do not act on LDL oxidation)
Patient Profile INTI Protocol Goal
Primary Prevention (LDL 3-4 mmol/L) 1 INTI/day daily oxLDL, basal endothelial NF-kB
Statins + residual risk 1-2 INTI/day Nrf2/HO-1, PCSK9 complement
Familial hypercholesterolemia Daily INTI (genetic context) Basic reduction of endothelial NF-kB
Medical Note: INTI does not replace statins or other lipid-lowering agents. Severe hypercholesterolemia requires pharmacological treatment. INTI can be safely consumed with statins (no significant CYP3A4 interaction at nutritional doses). Consult your doctor for LDL targets based on your cardiovascular risk.
Why is oxidized LDL more dangerous than total LDL?

Total LDL is a poor cardiovascular risk marker because some LDL (large buoyant LDL-A particles) is not very atherogenic. The real risk lies in small dense LDL particles (sdLDL) which easily penetrate the vascular intima and rapidly oxidize. oxLDL activates LOX-1 -> NF-kB -> foam cells. The ApoB/ApoA1 ratio or direct oxLDL measurement are better risk predictors than total LDL.

Can INTI replace a statin?

No. Statins reduce LDL-C by 30-55% depending on dose and molecule -- an effect that gingerol alone cannot match. INTI works on complementary mechanisms (LDL oxidation, endothelial NF-kB, PCSK9) not covered by statins. The combination of statin + INTI is more complete than either alone. Decisions about stopping or reducing statins should be made with a doctor.

INTI: Cardiovascular protection without sugar

1.19g sugar/100ml | oxLDL -38% | PCSK9 -28% | Nrf2/HO-1

Discover INTI

Related Articles

Read more about related topics :

Recommended Pages

Explore more about INTI :

Back to blog